PT - JOURNAL ARTICLE AU - Newcomer, Erin P. AU - Fishbein, Skye R. S. AU - Zhang, Kailun AU - Hink, Tiffany AU - Reske, Kimberly A. AU - Cass, Candice AU - Iqbal, Zainab H. AU - Struttmann, Emily L. AU - Dubberke, Erik R. AU - Dantas, Gautam TI - Genomic surveillance of <em>Clostridioides difficile</em> transmission and virulence in a healthcare setting AID - 10.1101/2023.09.26.23295023 DP - 2023 Jan 01 TA - medRxiv PG - 2023.09.26.23295023 4099 - http://medrxiv.org/content/early/2023/12/04/2023.09.26.23295023.short 4100 - http://medrxiv.org/content/early/2023/12/04/2023.09.26.23295023.full AB - Clostridioides difficile infection (CDI) is a major cause of healthcare-associated diarrhea, despite the widespread implementation of contact precautions for patients with CDI. Here, we investigate strain contamination in a hospital setting and genomic determinants of disease outcomes. Across two wards over six months, we selectively cultured C. difficile from patients (n=384) and their environments. Whole-genome sequencing (WGS) of 146 isolates revealed that most C. difficile isolates were from clade 1 (131/146, 89.7%), while only one isolate of the hypervirulent ST1 was recovered. Of culture-positive admissions (n=79), 19 (24%) of patients were colonized with toxigenic C. difficile on admission to the hospital. We defined 25 strain networks at ≤ 2 core gene SNPs; 2 of these networks contain strains from different patients. Strain networks were temporally linked (p&lt;0.0001). To understand genomic correlates of disease, we conducted WGS on an additional cohort of C. difficile (n=102 isolates) from the same hospital and confirmed that clade 1 isolates are responsible for most CDI cases. We found that while toxigenic C. difficile isolates are associated with the presence of cdtR, nontoxigenic isolates have an increased abundance of prophages. Our pangenomic analysis of clade 1 isolates suggests that while toxin genes (tcdABER and cdtR) were associated with CDI symptoms, they are dispensable for patient colonization. These data indicate toxigenic and nontoxigenic C. difficile contamination persists in a hospital setting and highlight further investigation into how accessory genomic repertoires contribute to C. difficile colonization and disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by an award to ERD and GD through the Foundation for Barnes-Jewish Hospital and Institute of Clinical and Translational Sciences. This publication was supported by the NIH/National Center for Advancing Translational Sciences (NCATS), grant UL1 TR002345 (PI: B. Evanoff). This work was also supported by funding through the CDC BAA #200-2018-02926 under PI Erik Dubberke. SRSF is supported by the National Institute of Child Health and Human Development (NICHD: https://www.nicdhd.nih/gov) of the NIH under award number T32 HD004010 (PI: P. Tarr). The conclusions from this study represent those of the authors and do not represent positions of the funding agencies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Washington University Human Research Protection Office (IRB #201810103). All participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated and analyzed during the current study are available in NCBI GenBank under BioProject accession no. PRJNA980715.BAPblood agar plateCCFA-HTCycloserine-Cefoxitin Fructose Agar with Horse Blood and TaurocholateCCMB-TALCycloserine Cefoxitin Mannitol Broth with Taurocholate and LysozymeCDIClostridioides difficile infectionEIAenzyme immunoassayHAIhealthcare-associated infectionHGThorizontal gene transferMALDI-TOF MSMatrix-assisted laser desorption/ionization-time of flight mass spectrometryNTCDnon-toxigenic C. difficilePaLocpathogenicity locus TCD, toxigenic C. difficileTSBtryptic soy broth